Long term treatment with omalizumab in adolescent with refractory solar urticaria

• Egile Nagusiak: Mauro Iannelli (Egilea), Stefano Passanisi (Egilea), Giuseppe Crisafulli (Egilea), Stefania Arasi (Egilea), Lucia Caminiti (Egilea), Giuseppina Zirilli (Egilea), Giovanni B. Pajno (Egilea)
• Formatua: Liburua
• Argitaratua: BMC, 2021-09-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Background Solar urticaria represents an uncomfortable form of chronic inducible urticaria. First and second-line treatments are ineffective in some patients, leading to an impairment in their quality of life. Omalizumab represents a safe therapeutic option in case of refractory solar urtic...